Targeting obesity subgroups

Both of the obesity therapeutics Orexigen Therapeutics Inc. is developing are oral, twice-daily combinations of approved drugs that include extended-release bupropion as one of their components. But the second component of each gives the two therapies different mechanisms of action that the company believes will be suited for different patient populations.

OREX presented full data from its Phase IIb trial of Empatic at the recent North American Association for the Study of Obesity (NAASO) meeting in New Orleans, as well as preclinical data on the mechanism of its more advanced compound, Contrave...